Fulcrum Therapeutics, Inc. Common Stock
FULCStock
$3.50−54.59%52W
Market Cap$232.22M
P/E—
Div yield—
Beta2.59
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-73.79%
Price vs S&P 500 (4W)2.29%
VGM Score47.41
Market Capitalization$232.22M
Earnings Surprise History
Q1 26-0.25est. -0.30
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.06
4.06
4.06
4.06
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FULCFulcrum Therapeutics, Inc. Common Stock | B | — | F | $3.50 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for genetically defined rare diseases. Its lead candidate, Pociredir, is an oral drug designed to induce fetal hemoglobin in patients with sickle cell disease; Phase 1b data demonstrated clinically meaningful HbF induction and improvements in hemolysis and anemia markers. The company maintains a pipeline of additional clinical and preclinical programs targeting the root causes of rare genetic disorders.